Citations

Clear

382 citation(s) found for "Li, Man".

Daily and Monthly Rhythm in the Blood Pressure of a Man With Hypertension: A Three-Year Study
BROWN, GEORGE E., BROWN, GEORGE E.

Mayo Clinic

Annals of Internal Medicine | April 11, 2013 | Volume: 3 | Issue: 12 | Pages: 1177-1189

10.7326/0003-4819-3-12-1177 Get It

Pulmonary Lymphangioleiomyomatosis in a Man
Aubry, Marie‐Christine, HENSKE, ELIZABETH PETRI, Logginidou, Helen, Jalal, Syed M., Tazelaar, Henry D. , Myers, Jeffrey L. , Ryu, Jay H. , Tazelaar, Henry D.

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | April 4, 2013 | Volume: 162 | Issue: 2 | Pages: 749-752

10.1164/ajrccm.162.2.9911006 | PMID 10934115 Get It

Abstract Pulmonary lymphangioleiomyomatosis (LAM) is an uncommon disease reported to occur exclusively in women. We describe a phenotypically normal man with pulmonary LAM. Fluorescence in situ hybridization (FISH) studies performed on the lung biopsy confirmed a normal XY genotype. Our patient also had stigmata of tuberous sclerosis complex (TSC), including facial angiofibromas and renal angiomyolipoma. Immunohistochemical stains of both LAM and renal angiomyolipoma showed positive immunoreactivity for hamartin (TSC1) and loss of immunoreactivity for tuberin (TSC2). Loss of heterozygosity (LOH) for TSC2 was further demonstrated in the renal angiomyolipoma. Coupled with the results of immunostains, these findings are consistent with TSC2 mutation.
Direct Effects of Exendin-(9,39) and GLP-1-(9,36)amide on Insulin Action, β-Cell Function, and Glucose Metabolism in Nondiabetic Subjects
Sathananthan, Matheni, Farrugia, Luca, Miles, John M., Piccinini, Francesca, Man, Chiara Dalla , Zinsmeister, Alan R., Rizza, Robert A., Miles, John J. , Miles, John M., Cobelli, Claudio , Vella, Adrian , Dalla Man, Chiara

Mayo Clinic

Diabetes | April 2, 2013 | Volume: 62 | Issue: 8 | Pages: 2752-2756

10.2337/db13-0140 | PMID 23545708 Get It

Exendin-(9,39) is a competitive antagonist of glucagon-like peptide-1 (GLP-1) at its receptor. However, it is unclear if it has direct and unique effects of its own. We tested the hypothesis that exendin-(9,39) and GLP-1-(9,36)amide have direct effects on hormone secretion and β-cell function as well as glucose metabolism in healthy subjects. Glucose containing [3-3H]glucose was infused to mimic the systemic appearance of glucose after a meal. Saline, GLP-1-(9,36)amide, or exendin-(9,39) at 30 pmol/kg/min (Ex 30) or 300 pmol/kg/min (Ex 300) were infused in random order on separate days. Integrated glucose concentrations were slightly but significantly increased by exendin-(9,39) (365 ± 43 vs. 383 ± 35 vs. 492 ± 49 vs. 337 ± 50 mmol per 6 h, saline, Ex 30, Ex 300, and GLP-1-[9,36]amide, respectively; P = 0.05). Insulin secretion did not differ among groups. However, insulin action was lowered by exendin-(9,39) (25 ± 4 vs. 20 ± 4 vs. 18 ± 3 vs. 21 ± 4 10−4 dL/kg[min per μU/mL]; P = 0.02), resulting in a lower disposition index (DI) during exendin-(9,39) infusion (1,118 ± 118 vs. 816 ± 83 vs. 725 ± 127 vs. 955 ± 166 10−14 dL/kg/min2 per pmol/L; P = 0.003). Endogenous glucose production and glucose disappearance did not differ significantly among groups. We conclude that exendin-(9,39), but not GLP-1-(9,36)amide, decreases insulin action and DI in healthy humans.
Drosophila melanogaster as an Emerging Translational Model of Human Nephrolithiasis
Miller, Joe, Chi, Thomas , Kapahi, Pankaj , Kahn, Arnold, Hirata, Taku, Romero, Michael F. , Dow, Julian A. T. , Stoller, Marshall L. , Kim, Man Su , Dow, Julian A T , Romero, Michael F

Mayo Clinic

Journal of Urology | March 8, 2013 | Volume: 190 | Issue: 5 | Pages: 1648-1656

10.1016/j.juro.2013.03.010 | PMID 23500641 Get It

Diurnal Pattern of Insulin Action in Type 1 Diabetes
Hinshaw, Ling , Man, Chiara Dalla , Nandy, Debashis, Saad, Ahmed , Bharucha, Adil E. , Levine, James A. , Rizza, Robert A., Basu, Rita , Carter, Rickey E. , Kudva, Yogish C. , Basu, Ananda , Cobelli, Claudio , Dalla Man, Chiara , Carter, Rickey E

Mayo Clinic

Diabetes | February 28, 2013 | Volume: 62 | Issue: 7 | Pages: 2223-2229

10.2337/db12-1759 | PMID 23447123 Get It

We recently demonstrated a diurnal pattern to insulin action (i.e., insulin sensitivity [SI]) in healthy individuals with higher SI at breakfast than at dinner. To determine whether such a pattern exists in type 1 diabetes, we studied 19 subjects with C-peptide–negative diabetes (HbA1c 7.1 ± 0.6%) on insulin pump therapy with normal gastric emptying. Identical mixed meals were ingested during breakfast, lunch, and dinner at 0700, 1300, and 1900 h in randomized Latin square of order on 3 consecutive days when measured daily physical activity was equal. The triple tracer technique enabled measurement of glucose fluxes. Insulin was administered according to the customary insulin:carbohydrate ratio for each participant. Although postprandial glucose excursions did not differ among meals, insulin concentration was higher (P < 0.01) and endogenous glucose production less suppressed (P < 0.049) at breakfast than at lunch. There were no differences in meal glucose appearance or in glucose disappearance between meals. Although there was no statistical difference (P = 0.34) in SI between meals in type 1 diabetic subjects, the diurnal pattern of SI taken across the three meals in its entirety differed (P = 0.016) from that of healthy subjects. Although the pattern in healthy subjects showed decreasing SI between breakfast and lunch, the reverse SI pattern was observed in type 1 diabetic subjects. The results suggest that in contrast to healthy subjects, SI diurnal pattern in type 1 diabetes is specific to the individual and cannot be extrapolated to the type 1 diabetic population as a whole, implying that artificial pancreas algorithms may need to be personalized.
Modeling hepatic insulin sensitivity during a meal: validation against the euglycemic hyperinsulinemic clamp
Man, Chiara Dalla , Piccinini, Francesca, Basu, Rita , Basu, Ananda , Rizza, Robert A., Cobelli, Claudio , Dalla Man, Chiara

Mayo Clinic

American Journal of Physiology-Endocrinology and Metabolism | February 27, 2013 | Volume: 304 | Issue: 8 | Pages: E819-E825

10.1152/ajpendo.00482.2012 | PMID 23443923 Get It

Recently, we proposed a model describing the suppression of endogenous glucose production (EGP) during a meal. It assumes that EGP suppression depends on glucose concentration and its rate of change and on delayed insulin action. Hepatic insulin sensitivity (SILmeal) can be derived from EGP model parameters. This model was shown to adequately describe EGP profiles measured with multiple tracer techniques; however, SILmealhas never been compared directly with its euglycemic hyperinsulinemic clamp counterpart (SILclamp). To do so, 62 subjects with different degrees of glucose tolerance underwent a triple-tracer mixed meal. Fifty-seven subjects also underwent a labeled ([3-3H]glucose) euglycemic hyperinsulinemic clamp. From the triple-tracer meal data, virtually model-independent estimates of EGP were obtained using the tracer-to-tracee clamp technique, and the EGP model was identified in each subject. Model fit was satisfactory, and SILmealwas estimated with good precision. Correlation between SILclampand SILmealwas good ( r = 0.72, P < 0.001); however, SILmealwas lower than SILclamp(4.60 ± 0.64 vs. 8.73 ± 1.07 10−4dl·kg−1·min−1per μU/ml, P < 0.01). This difference may be due to different ranges of insulin explored during the two tests (ΔIclamp= 15.60 ± 1.61 vs. ΔImeal= 83.37 ± 10.71 μU/ml) as well as steady- vs. non-steady-state glucose and insulin profiles. In conclusion, the new EGP model provides an estimate of hepatic insulin sensitivity during a meal that is in good agreement with that derived in the same individuals with a hyperinsulinemic clamp. When used in conjunction with the minimal model, the approach potentially enables estimation of hepatic insulin sensitivity from a single-tracer labeled meal or oral glucose tolerance test.
Clinical Reasoning: A 56-year-old man with progressive spasticity
Dhamija, Radhika , Raymond, Gerald V. , Gavrilova, Ralitza H. , Dhamija, Radhika

Mayo Clinic

Neurology | February 25, 2013 | Volume: 80 | Issue: 9 | Pages: No page available

10.1212/wnl.0b013e3182840729 | PMID 23439706 Get It

The Effect of a Bile Acid Sequestrant on Glucose Metabolism in Subjects With Type 2 Diabetes
Smushkin, Galina , Sathananthan, Matheni, Piccinini, Francesca, Man, Chiara Dalla , Law, Jennie H., Zinsmeister, Alan R., Rizza, Robert A., Cobelli, Claudio , Vella, Adrian , Dalla Man, Chiara

Mayo Clinic

Diabetes | December 19, 2012 | Volume: 62 | Issue: 4 | Pages: 1094-1101

10.2337/db12-0923 | PMID 23250357 Get It

We designed an experiment to examine the effect of bile acid sequestration with Colesevelam on fasting and postprandial glucose metabolism in type 2 diabetes. To do so, we tested the hypothesis that Colesevelam increases the disposition index (DI), and this increase is associated with increased glucagon-like peptide-1 (GLP-1) concentrations. Thirty-eight subjects on metformin monotherapy were studied using a double-blind, placebo-controlled, parallel-group design. Subjects were studied before and after 12 weeks of Colesevelam or placebo using a labeled triple-tracer mixed meal to measure the rate of meal appearance (Meal Ra), endogenous glucose production (EGP), and glucose disappearance (Rd). Insulin sensitivity and β-cell responsivity indices were estimated using the oral minimal model and then used to calculate DI. Therapy with Colesevelam was associated with a decrease in fasting (7.0 ± 0.2 vs. 6.6 ± 0.2 mmol/L; P = 0.004) and postprandial glucose concentrations (3,145 ± 138 vs. 2,896 ± 127 mmol/6 h; P = 0.01) in the absence of a change in insulin concentrations. Minimal model–derived indices of insulin secretion and action were unchanged. Postprandial GLP-1 concentrations were not altered by Colesevelam. Although EGP and Rd were unchanged, integrated Meal Ra was decreased by Colesevelam (5,191 ± 204 vs. 5,817 ± 204 μmol/kg/6 h; P = 0.04), suggesting increased splanchnic sequestration of meal-derived glucose.
ACR Appropriateness Criteria ® Spinal Bone Metastases
Lo, Simon Shek-Man, Lutz, Stephen, Chang, Eric L. , Galanopoulos, Nicholas, Howell, David D., Kim, Edward Y. , Konski, André , Pandit-Taskar, Neeta D., Rose, Peter S. , Ryu, Samuel , Silverman, Larry N., Sloan, Andrew E. , Poznak, Catherine Van

Mayo Clinic

Journal of Palliative Medicine | November 20, 2012 | Volume: 16 | Issue: 1 | Pages: 9-19

10.1089/jpm.2012.0376 | PMID 23167547 Get It

The Whole Life Prostate Book: Everything that Every Man—at Every Age—Needs to Know About Maintaining Optimal Prostate HealthCarterH.B. and CouzensG.S.: The Whole Life Prostate Book: Everything that Every Man—at Every Age—Needs to Know About Maintaining Opt
Myers, Robert P.

Mayo Clinic

Journal of Urology | October 22, 2012 | Volume: 188 | Issue: 6 | Pages: 2444-2444

10.1016/j.juro.2012.09.066 Get It